M. D. Anderson Cancer Center - News Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

MD Anderson receives $22.2 million in CPRIT research funding
The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 20, 2015 Category: Cancer & Oncology Source Type: news

ARCH Venture Partners, Flagship Ventures and MD Anderson collaborate to launch Codiak BioSciences
Codiak BioSciences, Inc. announced today the closing of the first portion of a planned $80-plus million Series A and B financing. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 17, 2015 Category: Cancer & Oncology Source Type: news

New York businessman, philanthropist gives $30 million to cancer research
Andy Sabin, of East Hampton, N.Y., has committed $30 million -- the philanthropist's largest grant to date -- to support research at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 16, 2015 Category: Cancer & Oncology Source Type: news

Research points to why some colorectal cancers recur after treatment
Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 16, 2015 Category: Cancer & Oncology Source Type: news

Study reveals why chemotherapy may be compromised in patients with pancreatic cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing  gemcitabine's ability to stop tumor growth. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 11, 2015 Category: Cancer & Oncology Source Type: news

Increased meat consumption, especially when cooked at high temperatures, linked to elevated kidney cancer risk
Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 9, 2015 Category: Cancer & Oncology Source Type: news

Dallas A Conversation With a Living Legend® to honor Dr. Condoleezza Rice
Former Secretary of State Condoleezza Rice is the honoree of A Conversation With a Living Legend®, benefiting The University of Texas MD Anderson Cancer Center, Tuesday Dec. 1 at the Hilton Anatole in Dallas. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 9, 2015 Category: Cancer & Oncology Source Type: news

CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 5, 2015 Category: Cancer & Oncology Source Type: news

First precision medicine trial in cancer prevention identifies molecular-based chemoprevention strategy
A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 5, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson's moon shots mission grows to confront six more cancer types
MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 29, 2015 Category: Cancer & Oncology Source Type: news

For lung cancer patients, IMRT associated with lesser side effects, better tolerance of chemotherapy, compared to conventional radiation therapy
An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that those who received intensity modulated radiation therapy (IMRT) had less severe lung toxicity and were able to better tolerate their chemotherapy, compared to patients who received 3-dimensional conformal radiation therapy (3-D CRT). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 19, 2015 Category: Cancer & Oncology Source Type: news

'Reversible' tumor suppressor loss: key to new brain cancer therapies?
It's no surprise that people enjoy warm places like Hawaii but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it is affected by the microenvironments of certain bodily organs to which it travels. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 19, 2015 Category: Cancer & Oncology Source Type: news

Study reveals why cancer anemia treatment leads to tumor growth
Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 15, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson to honor Houston Texans founder Bob McNair
Robert C. "Bob" McNair, founder, chairman and CEO of the Houston Texans, will be honored Nov. 4 at the eighth annual A Conversation With a Living Legend® in Houston benefiting The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 14, 2015 Category: Cancer & Oncology Source Type: news

'Until 20' Shares Courageous Story, Challenges All to Lead a Giving Life
Like the film itself, the world premiere of "Until 20" at the Austin Film Festival will be a celebration of James Ragan's life and his passion for family, friends, sports, a cure for childhood cancers and the mission of MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 14, 2015 Category: Cancer & Oncology Source Type: news